Author

R. Takahashi

3 papers indexed here

We haven’t gathered this author’s papers yet. Follow them and we’ll fetch their work.

Not the right person? Other researchers publish under this name.

Open access Sep 2026

Baseline CSF tau and short‐term clinical change during lecanemab therapy: A prospective real‐world cohort study in Japan

Abstract INTRODUCTION Real‐world prognostic evidence for cerebrospinal fluid (CSF) biomarkers during lecanemab therapy remains limited. We examined whether baseline CSF phosphorylated tau 181 (pTau181), total tau, and amyloid beta (Aβ) 42/Aβ40 were associated with 6‐month clinical change. METHODS This prospective singl...

R. Takahashi, Tetsuo Kashibayashi, Jun Fujita et al. · Alzheimer's & Dementia · 0 citations

Sep 2026

Lower baseline cerebrospinal fluid amyloid-β 42 is associated with amyloid-related imaging abnormalities during real-world lecanemab treatment.

Lower Aβ42 was associated with subsequent ARIA, but the internally derived cutoff requires external validation, and the internally derived cutoff requires external validation.

R. Takahashi, Tetsuo Kashibayashi, Jun Fujita et al. · Journal of Alzheimer's Disea... · 1 citation

Open access Aug 2026

White Matter Diffusion Anisotropy and the Effects of Inpatient Multidisciplinary Rehabilitation in Parkinson's Disease: A Diffusion Tensor Imaging Analysis.

With good internal discrimination and good internal discrimination, DTI-derived CST FA is a promising marker for stratifying rehabilitation potential, though external validation is required before clinical use.

K. Marumoto, Tetsuo Koyama, R. Takahashi et al. · Neurorehabilitation and Neur... · 0 citations